Skip to main content
. 2024 Aug 28;15:378. doi: 10.1007/s12672-024-01199-3

Fig. 3.

Fig. 3

Actionable genetic mutations identified in early-stage prostate adenocarcinoma. a evidence levels of the predicted biomarker function of the actionable mutations. b Frequency of actionable mutations according to the evidence levels. c Genes with high frequency of actionable mutations grouped according to evidence levels. d Drugs with predicted response related to actionable mutations